Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1966]

ESMO 2016: Expert discussion on prostate cancer: Treatment safety and...

Prof Bertrand Tombal and Dr Mark Beresford

ESMO 2016: Expert discussion on prostate cancer: Treatment safety and predictive markers ( Prof Bertrand Tombal and Dr Mark Beresford )

Advances for NSCLC in review

Dr Stefan Zimmermann - Hôpital Fribourgeois, Fribourg, Switzerland

Advances for NSCLC in review ( Dr Stefan Zimmermann - Hôpital Fribourgeois, Fribourg, Switzerland )

Atezolizumab v docetaxel for NSCLC: results from the OAK trial

Dr Fabrice Barlesi - Hôpital Nord, Marseille, France

Atezolizumab v docetaxel for NSCLC: results from the OAK trial ( Dr Fabrice Barlesi - Hôpital Nord, Marseille, France )

Significant survival gains with atezolizumab for NSCLC

Dr Fabrice Barlesi - Hôpital Nord, Marseille, France

Significant survival gains with atezolizumab for NSCLC ( Dr Fabrice Barlesi - Hôpital Nord, Marseille, France )

Pembrolizumab plus chemo as firstline therapy for NSCLC

Dr Corey Langer - University of Pennsylvania, Philadelphia, USA

Pembrolizumab plus chemo as firstline therapy for NSCLC ( Dr Corey Langer - University of Pennsylvania, Philadelphia, USA )

Pembrolizumab 'should be first line treatment' for high PD1 expressing NSCLC...

Dr Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany

Pembrolizumab 'should be first line treatment' for high PD1 expressing NSCLC patients ( Dr Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany )

Firstline pembrolizumab plus chemo improves NSCLC outcomes

Dr Corey Langer - University of Pennsylvania, Philadelphia, USA

Firstline pembrolizumab plus chemo improves NSCLC outcomes ( Dr Corey Langer - University of Pennsylvania, Philadelphia, USA )

Firstline pembrolizumab for metastatic urothelial cancer

Dr Arjun Balar - NYU Langone Medical Center, New York, USA

Firstline pembrolizumab for metastatic urothelial cancer ( Dr Arjun Balar - NYU Langone Medical Center, New York, USA )

Dabrafenib shows higher response and lower toxicity in paediatric brain cancer...

Dr Mark Kieran - Dana-Farber/Boston Children’s Cancer and Blood Disorders...

Dabrafenib shows higher response and lower toxicity in paediatric brain cancer trial ( Dr Mark Kieran - Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Boston, USA )

Outcome of ovarian cancer patients was significantly improved with niraparib

Dr Mansoor Raza Mirza - Copenhagen University Hospital, Copenhagen, Denmark

Outcome of ovarian cancer patients was significantly improved with niraparib ( Dr Mansoor Raza Mirza - Copenhagen University Hospital, Copenhagen, Denmark )

Ipilimumab as adjuvant therapy improves OS in high risk melanoma

Prof Alexander Eggermont - Institut Gustave Roussy, Villejuif, France

Ipilimumab as adjuvant therapy improves OS in high risk melanoma ( Prof Alexander Eggermont - Institut Gustave Roussy, Villejuif, France )

Ribociclib improves PFS for postmenopausal women with hormone receptor-positive...

Dr Gabriel Hortobagyi - MD Anderson, Houston, USA

Ribociclib improves PFS for postmenopausal women with hormone receptor-positive breast cancer ( Dr Gabriel Hortobagyi - MD Anderson, Houston, USA )

More from ecancer